Access Pharmaceuticals, Inc. (OTC BB: ACCP)

Access Pharmaceuticals, Inc. (OTC BB: ACCP), an emerging biopharmaceutical company, is committed to the development and commercialization of propriety products for the treatment and supportive care of cancer patients. Access’ products currently include ProLindac(TM), the company’s lead oncology drug which is currently in Phase 2 clinical testing; and MuGard(TM), a viscous, mucoadhesive rinse for the management of patients with mucositis. For further information, visit the Company’s web site at www.accesspharma.com.